TY - JOUR
T1 - Comparison of pentamidine isethionate andtrimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia
AU - Hughes, Walter T.
AU - Feldman, Sandor
AU - Chaudhary, Subhash C.
AU - Ossi, Michael J.
AU - Cox, Frederick
AU - Sanyal, S. K.
N1 - Funding Information:
From the Infectious Diseases and Cardiopulmonary Services, St. Jude Children's Research Hospital Supported by Childhood Cancer Research Center Grant CA-08480, National Cancer Institute, National Institutes of Health," American Cancer Society Training Grant 3608, Hoffmann-LaRoche Inc. and by A LSA C. Read in part before the Society for Pediatric Research, St. Louis, April, 1976. *Reprint address: The Children's Medical and Surgical Center, The Johns Hopkins Hospital, Baltimore, MD 21205.
PY - 1978/2
Y1 - 1978/2
N2 - Fifty patients with P. carinii pneumonitis were randomized to receive either pentamidine isethionate ortrimethoprim-sulfamethoxazole therapy. Those not responding favorably to the first drug after three or more days of therapy were changed to the alternate drug. Of the 26 patients initially treated with TMP-SMZ, 20 recovered (0.77)-17 after TMP-SMZ alone and three of nine who were crossed over to pentamidine. Of the 24 patients initially treated with pentamidine, 18 recovered (0.75)-14 of 15 who received only pentamidine and four of nine who were crossed over to TMP-SMZ. Abnormal values for blood urea nitrogen, creatinine, or glucose; inflammation at injection sites; or combination of these effects occurred in 14 of the 15 patients treated with pentamidine alone. Only one of the 17 patients treated with TMP-SMZ alone developed any of these abnormalities. This study shows that TMP-SMZ is as effective as pentamidine in the treatment of PCP, and that it offers the advantages of minimal adverse effects, oral administration, and ready availability.
AB - Fifty patients with P. carinii pneumonitis were randomized to receive either pentamidine isethionate ortrimethoprim-sulfamethoxazole therapy. Those not responding favorably to the first drug after three or more days of therapy were changed to the alternate drug. Of the 26 patients initially treated with TMP-SMZ, 20 recovered (0.77)-17 after TMP-SMZ alone and three of nine who were crossed over to pentamidine. Of the 24 patients initially treated with pentamidine, 18 recovered (0.75)-14 of 15 who received only pentamidine and four of nine who were crossed over to TMP-SMZ. Abnormal values for blood urea nitrogen, creatinine, or glucose; inflammation at injection sites; or combination of these effects occurred in 14 of the 15 patients treated with pentamidine alone. Only one of the 17 patients treated with TMP-SMZ alone developed any of these abnormalities. This study shows that TMP-SMZ is as effective as pentamidine in the treatment of PCP, and that it offers the advantages of minimal adverse effects, oral administration, and ready availability.
UR - http://www.scopus.com/inward/record.url?scp=0017834176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017834176&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(78)80028-6
DO - 10.1016/S0022-3476(78)80028-6
M3 - Article
C2 - 304478
AN - SCOPUS:0017834176
SN - 0022-3476
VL - 92
SP - 285
EP - 291
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 2
ER -